Cantor Fitzgerald Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $47
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has maintained an Overweight rating on Arrowhead Pharma (NASDAQ:ARWR) but lowered the price target from $79 to $47.
August 08, 2023 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arrowhead Pharma's price target has been lowered from $79 to $47 by Cantor Fitzgerald, though the Overweight rating is maintained.
The lowering of the price target by Cantor Fitzgerald indicates a potential decrease in the short-term value of Arrowhead Pharma's stock. However, the maintenance of the Overweight rating suggests that the analyst still sees potential for the stock to outperform its peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100